Sugi Predict

Sugi Predict / Compounds / SCHEMBL709637

SCHEMBL709637

SCHEMBL709637

CS(=O)(=O)OC[C@H]1CCCO1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.46
▸ POLB P06746 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ SCN9A Q15858 1/20 0.41
▸ PKM P14618 2/20 0.38
▸ CXCR4 P61073 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ NR2F2 P24468 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16640 1.00 LMNA (0.46) LMNAPOLBALDH1A1SCN9APKM
SCHEMBL419701 1.00 LMNA (0.46) LMNAPOLBALDH1A1SCN9APKM
SCHEMBL4640252 0.94 LMNA (0.41) LMNAPOLBALDH1A1SCN9ASMN1; SMN2
SCHEMBL709307 0.94 LMNA (0.41) LMNAPOLBALDH1A1SCN9ASMN1; SMN2
SCHEMBL8709127 0.94 LMNA (0.41) LMNAPOLBALDH1A1SCN9ASMN1; SMN2
SCHEMBL20266437 0.90 LMNA (0.36) LMNAPOLBALDH1A1SCN9ATSHR
SCHEMBL12747032 0.90 LMNA (0.36) LMNAPOLBALDH1A1SCN9ATSHR
SCHEMBL26687025 0.84 LMNA (0.49) LMNAPOLBALDH1A1SCN9APKM
SCHEMBL2198401 0.81 ALDH1A1 (0.39) LMNAPOLBALDH1A1SCN9APKM
SCHEMBL15074098 0.81 ALDH1A1 (0.39) LMNAPOLBALDH1A1SCN9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 — — US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 — — US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 — — US disclosed
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 — — US disclosed
US-20230391723-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2023-12-07 — — US disclosed
EP-4255904-A2 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2023-10-11 — — EP disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 — — US disclosed
WO-2022266458-A1 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
WO-2022266426-A1 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
US-20110028492-A1 Heteroaryl Compounds and Their Uses NOVARTIS AG (CH) 2011-02-03 — — US disclosed
WO-2011012661-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2011-02-03 — — WO disclosed
EP-1987006-B1 NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS (FR) 2011-01-12 — — EP disclosed
US-20090264403-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-10-22 — — US disclosed
EP-1987020-A1 AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS Sanofi-Aventis (FR) 2008-11-05 — — EP disclosed
WO-2007093364-A1 AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2007-08-23 — — WO disclosed
EP-0445862-B1 N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2000-04-19 — — EP disclosed
US-5262418-A Laxatives, gastrointestinal disorders TANSSEN PHARMACEUTICA N.V. (BE) 1993-11-16 — — US disclosed
US-5185335-A Administer to mammals to stimulate gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1993-02-09 — — US disclosed
EP-0445862-A2 N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1991-09-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A LMNA 1574/4885POLB 796/4885ALDH1A1 110/4885
US-20230391723-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A LMNA 1574/4885POLB 796/4885ALDH1A1 110/4885
US-20110028492-A1 Heteroaryl Compounds and Their Uses CDK9, CDK19, CDK3 LMNA 2184/4885POLB 440/4885ALDH1A1 2639/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS LMNA 3037/4885POLB 1532/4885ALDH1A1 2630/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A LMNA 1574/4885POLB 796/4885ALDH1A1 110/4885
US-20090264403-A1 NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS MCHR1, MRGPRX1, MRGPRX4 LMNA 2658/4885POLB 4275/4885ALDH1A1 1961/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A LMNA 1574/4885POLB 796/4885ALDH1A1 110/4885
US-20240066027-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 LMNA 1935/4885POLB 4651/4885ALDH1A1 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.